Abstract
Innovative attempts have been made to overcome nonproductivity and high expenditure in the clinical stages of new drug development. Microdosing studies using subpharmacological doses provide early insight into the body’s disposition toward candidate compounds, and are innovative exploratory trials that can promote productivity in drug development. Highly sensitive analytical technology is crucial in microdosing studies that employ qualitative and quantitative assays of target materials in humans. Accelerator mass spectrometry (AMS) has facilitated the adoption of a human microdosing study in the early phase of clinical drug development. Results derived from AMS microdosing studies using labeled compounds can provide various types of information for candidate selection, including pharmacokinetic characteristics and metabolic profiles of candidate compounds. The applicability of microdosing studies is currently expanding into absolute bioavailability and mass balance studies. Although it remains uncertain whether microdosing adequately predicts the pharmacokinetics of therapeutic doses, further development of microdosing studies using AMS may benefit the field of new drug development and could pose a new challenge to researchers. The use of advanced technology in candidate selection will contribute to improved productivity and competitiveness in pharmaceutical research and development. The introduction of microdosing studies using AMS in Korea will present a newly applicable method for innovative clinical trials and contribute to development potential in global competition.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Anderson, S., Knadler, M. P., and Luffer-Atlas, D., Overview of metabolite safety testing from an industry perspective. Bioanalysis, 2, 1249–1261 (2010).
Arjomand, A., Accelerator mass spectrometry-enabled studies: current status and future prospects. Bioanalysis, 2, 519–541 (2010).
Bauer, M., Wagner, C. C., and Langer, O., Microdosing studies in humans: the role of positron emission tomography. Drugs R D, 9, 73–81 (2008).
Brown, K., Dingley, K. H., and Turteltaub, K. W., Accelerator mass spectrometry for biomedical research. Methods Enzymol., 402, 423–443 (2005).
Budzikiewicz, H. and Grigsby, R. D., Mass spectrometry and isotopes: a century of research and discussion. Mass Spectrom. Rev., 25, 146–157 (2006).
Caskey, C. T., The drug development crisis: efficiency and safety. Annu. Rev. Med., 58, 1–16 (2007).
Combes, R. D., Berridge, T., Connelly, J., Eve, M. D., Garner, R. C., Toon, S., and Wilcox, P., Early microdose drug studies in human volunteers can minimise animal testing: Proceedings of a workshop organised by Volunteers in Research and Testing. Eur. J. Pharm. Sci., 19, 1–11 (2003).
DiMasi, J. A., Hansen R. W., and Grabowski, H. G., The price of innovation: new estimates of drug development costs. J. Health Econ., 22, 151–185 (2003).
European Medicines Evaluation Agency, Note for guidance on non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. http://www.emea.europa.eu/docs/en_GB/Document_library/Scientific_guideline/2009/09/WC500002720.pdf (2009).
EUMAPP, Outcomes from EUMAPP: A study comparing in vitro, in silico, microdose and pharmacological dose pharmacokinetics. http://www.eumapp.com/pdfs/EUMAPP%20 SUMMARY.pdf (2008).
Hah, S. S., Henderson, P. T., and Turteltaub, K. W., Recent advances in biomedical applications of accelerator mass spectrometry. J. Biomed. Sci., 16, 54 (2009).
Kim, S. H., Kelly, P. B., and Clifford, A. J., Biological/biomedical accelerator mass spectrometry targets. 1. optimizing the CO2 reduction step using zinc dust. Anal. Chem., 80, 7651–7660 (2008).
Kim, S. H., Kelly, P. B., Ortalan, V., Browning, N. D., and Clifford, A. J., Quality of graphite target for biological/biomedical/environmental applications of 14C-accelerator mass spectrometry. Anal. Chem., 82, 2243–2252 (2010).
Kimmelman, J., Ethics at phase 0: clarifying the issues. J. Law Med. Ethics, 35, 727–733 (2007).
Lappin, G. and Garner, R. C., Big physics, small doses: the use of AMS and PET in human microdosing of development drugs. Nat. Rev. Drug Discov., 2, 233–240 (2003).
Lappin, G. and Garner, R. C., The use of accelerator mass spectrometry to obtain early human ADME/PK data. Expert Opin. Drug Metab. Toxicol., 1, 23–31 (2005).
Lappin, G., Kuhnz, W., Jochemsen, R., Kneer, J., Chaudhary, A., Oosterhuis, B., Drijfhout, W. J., Rowland, M., and Garner, R. C., Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Clin. Pharmacol. Ther., 80, 203–215 (2006).
Lappin, G. and Garner, R. C., The utility of microdosing over the past 5 years. Expert Opin. Drug Metab. Toxicol., 4, 1499–1506 (2008).
Lappin, G., Shishikura, Y., Jochemsen, R., Weaver, R. J., Gesson, C., Brian Houston, J., Oosterhuis, B., Bjerrum, O. J., Grynkiewicz, G., Alder, J., Rowland, M., and Garner, C., Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers. Eur. J. Pharm. Sci., 43, 141–150 (2011).
Lewis, L. D., Early human studies of investigational agents: dose or microdose? Br. J. Clin. Pharmacol., 67, 277–279 (2009).
Liberman, R. G., Tannenbaum, S. R., Hughey, B. J., Shefer, R. E., Klinkowstein, R. E., Prakash, C., Harriman, S. P., and Skipper, P. L., An interface for direct analysis of 14C in nonvolatile samples by accelerator mass spectrometry. Anal. Chem., 76, 328–334 (2004).
Madan, A., O’Brien, Z., Wen, J., O’Brien, C., Farber, R. H., Beaton, G., Crowe, P., Oosterhuis, B., Garner, R. C., Lappin, G., and Bozigian, H. P., A pharmacokinetic evaluation of five H(1) antagonists after an oral and intravenous microdose to human subjects. Br. J. Clin. Pharmacol., 67, 288–298 (2009).
Marchetti, S. and Schellens, J. H., The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials. Br. J. Cancer, 97, 577–581 (2007).
Mayr, L. M. and Bojanic, D., Novel trends in high-throughput screening. Curr. Opin. Pharmacol., 9, 580–588 (2009).
Miyaji, Y., Ishizuka, T., Kawai, K., Hamabe, Y., Miyaoka, T., Oh-hara, T., Ikeda, T., and Kurihara, A., Use of an intravenous microdose of 14C-labeled drug and accelerator mass spectrometry to measure absolute oral bioavailability in dogs; cross-comparison of assay methods by accelerator mass spectrometry and liquid chromatographytandem mass spectrometry. Drug Metab. Pharmacokinet., 24, 130–138 (2009).
Mucke, H. A. M., Microdosing in translational medicine: pros and cons. CHI Insight Pharma Reports, 2006
Robinson, W. T., Innovative early development regulatory approaches: expIND, expCTA, microdosing. Clin. Pharmacol. Ther., 83, 358–360 (2008).
Salehpour, M., Forsgard, N., and Possnert, G., FemtoMolar measurements using accelerator mass spectrometry. Rapid Commun. Mass Spectrom., 23, 557–563 (2009).
Salehpour, M., Ekblom, J., Sabetsky, V., Håkansson, K., and Possnert, G., Accelerator mass spectrometry offers new opportunities for microdosing of peptide and protein pharmaceuticals. Rapid Commun. Mass Spectrom., 24, 1481–1489 (2010).
Sarapa, N., Hsyu, P. H., Lappin, G., and Garner, R. C., The application of accelerator mass spectrometry to absolute bioavailability studies in humans: simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers. J. Clin. Pharmacol., 45, 1198–1205 (2005).
US FDA, Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077262.htm (2004).
US FDA, Investigators, and Reviewers Exploratory IND Studies. http://www.fda.gov/ohrms/dockets/98fr/05d-0122-gdl0002.pdf (2006).
US FDA, Guidance for Industry Safety Testing of Drug Metabolites. http://www.fda.gov/OHRMS/DOCKETS/98fr/FDA-2008-D-0065-GDL.pdf (2008).
Vogel, J. S., Turteltaub, K. W., Finkel, R., and Nelson, D. E., Accelerator mass spectrometry. Anal. Chem., 67, 353A–359A (1995).
Vuong, le T., Ruckle, J. L., Blood, A. B., Reid, M. J., Wasnich, R. D., Synal, H. A., and Dueker, S. R., Use of accelerator mass spectrometry to measure the pharmacokinetics and peripheral blood mononuclear cell concentrations of zidovudine. J. Pharm. Sci., 97, 2833–2843 (2008).
Wilding, I. R. and Bell, J. A., Improved early clinical development through human microdosing studies. Drug Discov. Today, 10, 890–894 (2005).
Yamane, N., Tozuka, Z., Sugiyama, Y., Tanimoto, T., Yamazaki, A., and Kumagai, Y., Microdose clinical trial: quantitative determination of fexofenadine in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 858, 118–128 (2007).
Young, G., Ellis, W., Ayrton, J., Hussey, E., and Adamkiewicz, B., Accelerator mass spectrometry (AMS): recent experience of its use in a clinical study and the potential future of the technique. Xenobiotica, 31, 619–632 (2001).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Bae, S.K., Shon, JH. Microdosing studies using accelerated mass spectrometry as exploratory investigational new drug trials. Arch. Pharm. Res. 34, 1789–1798 (2011). https://doi.org/10.1007/s12272-011-1102-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-011-1102-3